Precision Dosing of Targeted Therapies Is Ready for Prime Time

Area of Science:

• Pharmacology
• Oncology
• Precision Medicine

Background:

• Fixed dosing of oral targeted therapies is insufficient in precision medicine.
• Personalized dosing, guided by pharmacokinetic (PK) exposure (therapeutic drug monitoring, TDM), is increasingly supported by evidence.
• PK-based dose adjustments are standard practice for specific patient groups and drug interactions.

Purpose of the Study:

• To discuss the necessity of randomized studies for confirming the clinical value of precision dosing in oncology.
• To explore the logical extrapolation of PK-guided dosing from population-based adjustments to individual patient optimization.
• To propose a framework for demonstrating the clinical relevance of individualized dosing for molecularly-targeted anticancer drugs.

Main Methods:

• Literature review and synthesis of existing evidence on PK-guided dosing.
• Logical argumentation based on the relationship between drug exposure, clinical outcomes (efficacy, toxicity), and dose optimization.
• Development of a proposed pathway for future research and validation.

Main Results:

• The principle of PK-guided dose adjustment is already established and accepted for specific scenarios.
• If exposure-outcome relationships are known and optimization is feasible, personalized dosing is logically expected to improve outcomes.
• Randomized trials may not be the only or most efficient method to demonstrate the value of precision dosing.

Conclusions:

• Personalized, PK-guided dosing represents a rational extension of established pharmacologic principles.
• The clinical utility of precision dosing in oncology can be demonstrated without necessarily requiring large-scale randomized controlled trials.
• A clear path forward exists to validate and implement individualized dosing strategies for molecularly-targeted anticancer agents.